Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$10.33 USD

10.33
4,776,516

-0.73 (-6.60%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $10.33 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54%

by Zacks Equity Research

ACELYRIN (SLRN) fails to achieve statistically significant primary endpoint result in the hidradenitis suppurativa study of its lead candidate, izokibep. The stock of the company falls 54%.

Zacks Equity Research

Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up

by Zacks Equity Research

Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure activity. The stock rises 4.7% in response.

Zacks Equity Research

Bicycle (BCYC) to Begin Pivotal Bladder Cancer Study, Stock Up

by Zacks Equity Research

Bicycle (BCYC) aligns with the FDA on the design of a mid-late-stage registrational study for its bladder cancer drug, BT8009, with the potential to support its accelerated approval. The stock rises 9%.

Zacks Equity Research

J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe

by Zacks Equity Research

J&J's (JNJ) erdafitinib is already marketed as Balversa in the United States for FGFR-altered metastatic UC. Balversa is approved by the FDA under the accelerated pathway.

Zacks Equity Research

Bristol Myers' (BMY) Pulmonary Fibrosis Drug Positive in Phase II

by Zacks Equity Research

Bristol Myers (BMY) posts encouraging data from a phase II study in progressive pulmonary fibrosis.

Zacks Equity Research

Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study

by Zacks Equity Research

Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.

Zacks Equity Research

Codexis (CDXS) Transfers Leasing Rights to Vaxcyte, Stock Up

by Zacks Equity Research

Codexis (CDXS) transfers the leasing rights of its San Carlos, CA location to Vaxcyte to focus on technology development, inducing cost savings, to extend its cash runway to mid-2026. The stock rises 7%.

Kinjel Shah headshot

Merck's (MRK) Ebola Vaccine Gets Approval for Kids in Europe

by Kinjel Shah

The European Commission approves Merck's (MRK) Ebola vaccine for use in children as young as one year.

Zacks Equity Research

CymaBay (CBAY) Stock Up on Positive Results From PBC Study

by Zacks Equity Research

CymaBay (CBAY) reports encouraging data from the phase III study of seladelpar in PBC patients. Stock up.

Zacks Equity Research

Alnylam's (ALNY) Zilebesiran Meets Goals in Mid-Stage Study

by Zacks Equity Research

Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.

Zacks Equity Research

Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights

by Zacks Equity Research

Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.

Zacks Equity Research

NeuBase (NBSE) Surges 107% on New Shareholder Acquiring Stake

by Zacks Equity Research

With NeuBase (NBSE) exploring strategic alternatives to the company, Symetryx joins the company's shareholder base and urges the board to issue a unique $1 per share dividend.

Zacks Equity Research

J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit

by Zacks Equity Research

The decision to end the CTEPH study on J&J's (JNJ) Opsumit (macitentan) was made at the recommendation of the study's independent DMC, following a pre-planned interim analysis.

Zacks Equity Research

Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why

by Zacks Equity Research

Mirum Pharma (MIRM) surges 42% year to date due to encouraging progress in label-expansion efforts of Livmarli, along with strategic initiatives, to expand its commercial portfolio.

Zacks Equity Research

BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study

by Zacks Equity Research

Based on one-year follow-up data from a pivotal phase III study, BioCardia (BCDA) reveals that its CardiAMP cell therapy is unlikely to achieve the primary endpoint for the treatment of heart failure.

Zacks Equity Research

AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication

by Zacks Equity Research

AstraZeneca (AZN) said the CRL for Ultomiris for NMOSD indication does not raise any concerns about the efficacy and safety data from the study.

Zacks Equity Research

Roche's (RHHBY) Application for PNH Drug Accepted by FDA

by Zacks Equity Research

Roche (RHHBY) biologics license application seeking approval for crovalimab for paroxysmal nocturnal hemoglobinuria gets FDA acceptance.

Zacks Equity Research

Novo Nordisk (NVO) Launches Wegovy in UK Amid Supply Issues

by Zacks Equity Research

Novo Nordisk (NVO) announces the controlled and limited launch of Wegovy in the U.K. amid rising demand for weight loss treatment and supply constraints.

Zacks Equity Research

Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids

by Zacks Equity Research

Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.

Zacks Equity Research

Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.

Zacks Equity Research

Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals

by Zacks Equity Research

Seagen (SGEN) and Genmab announce that the late-stage study of Tivdak in the second-line treatment of adult patients with recurrent or metastatic cervical cancer meets the primary and secondary goals.

Zacks Equity Research

FTC Allows Amgen (AMGN) to Proceed With $28B Horizon Buyout

by Zacks Equity Research

Per the settlement terms, Amgen (AMGN) is prohibited from bundling its products with Horizon's Tepezza or Krystexxa. Amgen expects to complete the Horizon acquisition before 2023-end.

Zacks Equity Research

Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why

by Zacks Equity Research

Centessa (CNTA) shares rise significantly in the past three months due to the encouraging progress in the development of its lead pipeline candidate, SerpinPC, which is currently in mid-late-stage studies.

Ekta Bagri headshot

5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.

Zacks Equity Research

Roche's (RHHBY) Late-Stage Lung Cancer Study Meets Primary Goal

by Zacks Equity Research

Roche's (RHHBY) late-stage ALK-positive non-small cell lung cancer study evaluating Alecensa meets the primary endpoint of disease-free survival.